FDA clears Boston Scis Renegade HI-FLO for embolisms
The FDA has approved Boston Scientific’s Renegade HI-FLO Fathom system for selective access and delivery of diagnostic, embolic and therapeutic materials to the peripheral vasculature.
According to company, the Renegade HI-FLO is intended for use by interventional radiologists to treat uterine fibroids and liver cancer. Natick, Mass.-based Boston Scientific said that the system combines turn-for-turn torque response with the Fathom-16 and the Renegade HI-FLO Microcatheter pre-loaded as a single platform, which will be adaptable to a range of embolization procedures via eight configurations.
According to company, the Renegade HI-FLO is intended for use by interventional radiologists to treat uterine fibroids and liver cancer. Natick, Mass.-based Boston Scientific said that the system combines turn-for-turn torque response with the Fathom-16 and the Renegade HI-FLO Microcatheter pre-loaded as a single platform, which will be adaptable to a range of embolization procedures via eight configurations.